Reshaping
gynecological
diagnostics.

Who we are

At MiMARK we care for women’s health. We are developing innovative in vitro diagnostic solutions to improve the management of gynecological malignancies. We envision the gynecological fluid as the next step in liquid biopsy in gynecology. Our first objective is to improve Endometrial Cancer diagnosis.

Our commited team

FOUNDERS

Marina Rigau
CEO & Co-Founder

Eva Colás,
CSO & Co-Founder

Antonio Gil,
CMO & Co-Founder

TEAM

Todd Snowden
CBO, Chief Business Officer

Mar Cedó
CTO, Chief Technology Officer

Jordi Petit
Financial Lead

Cristina Vilarmau
Innovation Manager

Nuria Palomar
RA & QA Manager

Roger Canton
Clinical Manager

Andreas Avgousti
Grant Manager

Guillem Loren
Innovation Assistant

María de Martí
Senior Scientist

Javier Carvajal
Industrial Ph.D. Student

Astrid Garcia
Lab technician

Laia Escalé
Biobank technician

ADVISORS

Helene
Peyro-Saint-Pau
Business Advisor

Ramón Benet
Business Advisor

Javier F. Magriña
Medical advisor

Frederic Amant
Medical advisor

Denis Querleu
Medical advisor

Michele Pedrocchi
Business Advisor

Our approach for transforming
gynaecological care

The future of
Endometrial Cancer Diagnosis

Unmet clinical need

Abnormal vaginal bleeding affects 12M post-menopausal women in EU and US yearly. Diagnosis of endometrial cancer is mandatory since 10% of these women will suffer it. Current diagnosis is based on the pathological examination of an endometrial biopsy (pipelle biopsy), but this fails to diagnose 31% of patients, and provides an inaccurate diagnosis in 55% of cases. This failure is associated to the scarce cellularity of the sample. In those cases, invasive diagnosis using histeroscopy needs to be performed.

ENDOMETRIAL CANCER
4th
most common cancer
6th
most deathly cancer

IVD test based on a panel of 5 protein biomarkers present in uterine fluids to detect EC.

Our solution: WomEC

WomEC is an in-vitro diagnostic immunoassay for the detection of Endometrial Cancer (EC) based on the quantification of the expression level of proteins in the soluble fraction (no cellular material required) of a pipelle biopsy specimen. By using uterine fluid rather than cellular material for EC diagnosis, WomEC can provide a highly accurate diagnosis – with 99 percent sensitivity, 79 percent specificity, 97 percent negative predictive value and 87 percent positive predictive value – on all subjects undergoing the diagnostic procedure for EC. In addition, WomEC provides information regarding the tumor classification of EC to be used for treatment planning and surgical decision-making (pre-operative risk assessment).

WomEC is being developed as an immunoassay test to facilitate its implementation in clinical laboratories.

How will it impact the healthcare system

To PATIENTS

Less invasive, with lower risk of complications and pain when avoiding hysteroscopies (31% cases)

Less waiting time and stress: from 1-month to 2-day diagnosis

Increased life expectancy: early diagnosis & optimal surgery

Improved QALYs: personalized/optimal surgery plan

To DOCTORS

Accurate & objective diagnosis vs subjective pathology

Faster diagnosis & easy patient management from 1 month to 2-day diagnosis

Rule out benign patients safely, send home with no need of hysteroscopy (31% of cases)

Rule in high-risk EC patients to referral centers with optimal surgery plan

To PAYERS

More efficient patient management: reduced unnecessary procedures

Lower annual cost of care by avoiding hysteroscopies (average cost: USD 1,900 in US and 500€ in EU)

OUTCOMES IMPACT
Two EU patents have been already accepted in several regions. Well protected asset
Five clinical retrospective studies involving more than
600 patients using mass spectrometry (LC-PRM)
technology and ELISA assay
Protein accuracy in clinical setting.
International publications:

– Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples. Oncotarget 2016.
– Advances in endometrial cancer protein biomarkers for use in the clinic. Expert Rev Proteomics 2017
– Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment. Clin Ca Research 2017

Propietary antibodies developed Prototype feasibility
Validation of the clinical need
+250 gynecologists and pathologists
Clinical relevance
Currently
finishing the prototype development stage with
proprietary antibodies
Prototype development

We seek partners to foster WomEC development,
validation and commercialization

Key Opinion Leaders are supporting WomEC

“WomEC will revolutionize uterine cancer diagnosis in the world”

Javier F. Magrina,
Director Gynecologic Oncology

“From a clinical perspective, the project is expected to benefit the European community”

Frederic Amant,
Head of the gynecology oncology department,
ex-chairman of the ENITEC consortium

Contact us

    Investors:

    Public Funding Sources:

    Partners: